Piton Therapeutics, is at the forefront of a revolution in the discovery and development of precision therapeutics for chronic and systemic diseases.
Current focus is on developing first-in-class, precision therapeutics for neurological, metabolic, and inflammatory diseases.
Piton approaches drug development uniquely by exploiting the causal role of our gut microbiome in disease to create innovative, precision therapeutics. The application of both large and small molecule drugs to accurately target mechanisms of action in the gut microbiome signifies an evolution in precision targeting and disease specificity in microbiome-focused therapeutics.
As a leader in the field, Piton utilizes sophisticated platform discovery capabilities to quickly understand the compositional and functional makeup of the microbiome. This information is compiled into disease-specific, multidimensional, ecological models of the gut microbiome, which are examined to identify causal factors. Piton's proprietary, AI-enabled drug discovery engine facilitates efficient and effective selection of lead molecules.
The company's orally dosed, gut-restricted therapeutics, designed to have minimal side effects, have the potential to revolutionize the care paradigm for hundreds of millions of patients.
Piton's world-class team has a strong record of advancement. The company is currently conducting Investigational New Drug (IND)-enabling studies for precision, small molecule drugs targeted at treating Ulcerative Colitis and Type 2 Diabetes. In addition, a drug for Autism Spectrum Disorder is being optimized, and research into a causal hypothesis for Parkinson's Disease is ongoing.